New developments in imaging cell-based therapy

Olivier Martinez, Jane Sosabowski, John Maher, Sophie Papa*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Cancer immunotherapy is now established as a central therapeutic pillar in hematologic oncology. Cell-based therapies, with or without genetic modification ex vivo, have reached the clinic as the standard of care in limited indications and remain the subject of intense preclinical and translational development. Expanding on this, related therapeutic approaches are in development for solid-tumor and nonmalignant indications, broadening the scope of this technology. It has long been recognized that in vivo tracking of infused cellular therapies would provide unique opportunities to optimize their efficacy and aid in the assessment and management of toxicity. Recently, we have witnessed the introduction of novel tracers for passive labeling of cell products and advances in the introduction and use of reporter genes to enable longitudinal imaging. This review highlights the key developments over the last 5 y.

Original languageEnglish
Pages (from-to)730-735
Number of pages6
JournalJournal of Nuclear Medicine
Volume60
Issue number6
DOIs
Publication statusE-pub ahead of print - 12 Apr 2019

Keywords

  • Cell therapy
  • Molecular imaging
  • Oncology
  • Radioimmunoimaging
  • Radiotracers

Fingerprint

Dive into the research topics of 'New developments in imaging cell-based therapy'. Together they form a unique fingerprint.

Cite this